At the news
? BEARISHIMPACT 7/10 425 filed Aug 17, 2026 at 08:33 ET
Fulcrum Therapeutics (FULC) filed a Rule 425 transcript of a joint conference call with Slate Medicines, confirming the all-stock merger announced August 16, 2026. The call reiterates the deal structure: Fulcrum stockholders will own ~5% of the combined company, Slate stockholders ~55.9%, PIPE investors ~39.1%, with a special cash dividend of excess cash above $20.3M to pre-merger Fulcrum holders. The deal transforms FULC into a migraine-focused biotech under Slate management (ticker expected to become SLTE), funded by a $245M PIPE providing cash runway into 2029.
- Pre-merger Fulcrum stockholders to own ~5% of the combined company on a fully-diluted basis (down from 100% control).
- Pre-merger Slate stockholders to own ~55.9%, PIPE investors ~39.1%.
- Fulcrum to contribute net cash of $20.3M at close, with excess cash (~$270M) paid as a special dividend to pre-merger Fulcrum holders.
- $245M concurrent private placement led by Frazier Life Sciences with participation from Forbion, RA Capital, Deep Track, Foresite, OrbiMed, RTW, Mingxin.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access